

This information is intended for healthcare professional use only.
It is not to be shown to or shared with patients.

DETERMINED TO PROTECT WHAT MATTERS MOST

The image depicted contains models and is being used for illustrative purposes only.

Are you treating a pregnancy at risk for severe HDFN?

Learn more about the Azalea clinical research study of an investigational medication in pregnancies at risk for severe HDFN.

What is the purpose of the study?

The purpose of this study is to evaluate the safety and efficacy of an investigational medication in pregnancies at risk for severe HDFN.

The Azalea Clinical Trial is Enrolling Participants Who:

- Have tested positive for red cell antibodies
- Have been diagnosed with HDFN in a prior pregnancy
- Are 18 to 45 years old

Additional eligibility criteria will be assessed by the study team.

What will happen during the Azalea study?

Potential participants will be asked to attend a screening visit with the study doctor where they will undergo tests and procedures to determine if they are an appropriate match for participating in the study.

Participation in this clinical trial includes weekly intravenous (IV) infusions while the participant visits the trial site approximately 18 - 23 times during their pregnancy. After their child's birth, they will have three additional trial site visits over the course of six months, and the child will have six trial site visits over the course of two years.

Participants in the Azalea study will be randomly assigned to receive an infusion of the investigational medication; this can be the active investigational medication or placebo (the randomisation ratio is 2:1, respectively).

All participants in the clinical trial will be reimbursed for study required travel and receive study required medical care at no cost. The investigational medication will be provided at no cost to participants. Participants will not be paid for other medical care or medications which are not part of the study. The investigational medication has not been approved for use by the Therapeutic Goods Administration in Australia.

Participants should continue taking all current medications as prescribed.